NEW YORK, NY (Jan. 25, 2017)—Loss of function of the CRKL gene causes kidney and urinary tract defects in people with DiGeorge syndrome, a multinational team of scientists led by Columbia University Irving Medical Center (CUIMC) has found.
Findings of their study were published online today in the New England Journal of Medicine.
“This study represents a critical step forward in understanding the genetic basis of congenital kidney defects associated with DiGeorge syndrome and in the general population,” said Simone Sanna-Cherchi, MD, assistant professor of medicine at Columbia. “Expanding our knowledge of the genetics of kidney development and malformations will give us additional tools needed to diagnose this variant of DiGeorge syndrome and gives us a potential therapeutic target.”
DiGeorge syndrome is a chromosomal disorder that can lead to malformations in multiple organs. It is the most common microdeletion syndrome, in which a portion of a chromosome is missing. The condition occurs when the q11.2 segment of one copy of the 22nd chromosome is deleted. Deletion of this segment, which includes more than 40 genes, can affect the development of the heart, nervous system, kidneys, and other organs and body systems.
Scientists do not fully understand the function of many of the genes affected by DiGeorge syndrome. Previously, researchers had identified loss of the TBX1 gene as the source of congenital heart malformations in people with DiGeorge syndrome. However, they had not yet found the cause of congenital kidney and urinary tract defects, which occur in approximately 30 percent of DiGeorge patients.
In this study, the investigators performed genomic analyses in 2,666 children with congenital anomalies of the kidney and urinary tract—the largest pediatric cohort of these disorders—and 22,094 controls to identify structural variants associated with these defects.
The analysis identified deletions at the terminal portion of the 22q11.2 DiGeorge locus as the second most common microdeletion in patients with kidney malformations. This study mapped the candidate gene for kidney disease in DiGeorge syndrome to a smaller region containing only nine genes. By testing the function of each gene in zebrafish embryos, the authors showed that three candidate genes appeared to cause kidney malformations, and loss of function in CRKL alone was capable of causing kidney and urinary tract defects. Resequencing of all genes included in the critical 22q11.2 region identified five out of 586 patients with kidney and urinary tract defects that had novel heterozygous protein-altering variants, including a premature termination codon, in CRKL. Inactivation of the same gene in mouse embryos finally proved its role as the main driver.
“This discovery allowed us to solve a 60-year-old medical mystery about the cause of kidney disease in people with DiGeorge syndrome,” said Miguel Verbitsky, PhD, associate research scientist in the Department of Medicine at CUIMC and co-author of the paper. “It is one of the strongest genetic associations in the field of nephrology and confirms the utility of our multidisciplinary approach in a large pediatric cohort.”
Previously, Dr. Sanna-Cherchi’s team revealed a link between congenital kidney malformations and neurodevelopmental disorders such as autism, schizophrenia, intellectual disability, and epilepsy.
Patients with DiGeorge syndrome are at high risk for intellectual disability, schizophrenia, and other neurocognitive problems, so the researchers now hope to determine whether CRKL gene function is critical for brain development as well as kidney and urinary tract development.
“The study may also shed more light on the kidney-brain axis that we previously identified,” said Dr. Sanna-Cherchi. “Future research will help us understand the downstream mechanisms that link genetic variations in CRKL to kidney malformations and, possibly, neurocognitive problems.”
The study is titled “Genetic Drivers of Kidney Defects in the DiGeorge Syndrome.”
Authors from Columbia University Irving Medical Center included Ester Lopez-Rivera, Miguel Verbitsky, Valentina P. Capone, Zhonghai Yan, Adele Mitrotti, Jeremiah Martino, Nicholas J. Steers, David A. Fasel, Rong Deng, Max Werth, Gabriel S. Makar, Monica Bodria, Donald S. Petry, Qingxue Liu, Barry Honig, Krzysztof Kiryluk, Vivette D’Agati, Ali G. Gharavi, Virginia E. Papaioannou, and Simone Sanna-Cherchi.
Nicholas Katsanis (Duke University School of Medicine) was a co-senior author.
A complete list of authors can be found in the paper.
The study was supported by the National Institutes of Health (grants 1R01DK103184(link is external and opens in a new window), 1R21DK098531(link is external and opens in a new window), UL1TR000040(link is external and opens in a new window), P50DK096415(link is external and opens in a new window), P30DK096493(link is external and opens in a new window), 2R01DK080099(link is external and opens in a new window), U54DK104309(link is external and opens in a new window), P01HD070454(link is external and opens in a new window), 4R01GM030518(link is external and opens in a new window), R37HD033082(link is external and opens in a new window), and 1R01DK105124(link is external and opens in a new window)), the American Heart Association, the Joint Italian Ministry of Health and NIH Young Investigators Finalized Research, the National Human Genome Research Institute Centers for Mendelian Genomics, the Fondazione Malattie Renali nel Bambino, the GIS-Institut des Maladies Rares, the Programme Hospitalier de la Recherche, the Polish Ministry of Health, the Polish Kidney Genetics Network, the Polish Registry of Congenital Malformations, the NZOZ Center for Medical Genetics, the National Institute of Diabetes and Digestive and Kidney Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Heart, Lung, and Blood Institute, and the Paul Marks Scholar Award.
The authors declare no conflicts of interest.
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. Columbia University Irving Medical Center shares a campus with its hospital partner, NewYork-Presbyterian. For more information, visit cuimc.columbia.edu or columbiadoctors.org.